Since disruption of the BBB is a poor prognostic factor of anti-NMDAR encephalitis, the measurement of CD44 and MMP9 in CSF and serum can be used as a potential biomarker to indicate its prognosis in the clinical arrangement. This evidence concerns the gene CD44 and encephalitis.